Moderna stock faces Nov. 6 test as oncology promise meets scale risk

Moderna is approaching a decisive earnings checkpoint as investors weigh a stronger oncology pipeline against the still uncertain recovery of its respiratory vaccine business. The company is scheduled to report third-quarter results before the U.S. market opens on Friday, November 6.

In October, Moderna and Merck reported Phase 3 results for intismeran autogene combined with Keytruda in patients with completely resected, high-risk melanoma. The combination reduced the risk of recurrence or death by 42 percent and the risk of distant metastasis or death by 38 percent versus Keytruda alone. Overall survival data remain immature, so the result strengthens the development case without settling the eventual commercial outcome.

What investors are watching next

Yahoo Finance, citing Zacks Investment Research, reported consensus expectations of 888.8 million US dollars in quarterly sales and a loss of 1.37 US dollars per share. The report also identified management commentary on regulatory submissions and progress across nine additional Phase 2 and Phase 3 studies as potential investor focus points.

That leaves two separate tests for the November report. The first is whether seasonal demand for COVID-19, influenza and RSV products can support Moderna's near-term revenue outlook. The second is whether management can provide a clearer timetable for advancing intismeran toward regulatory submissions while continuing to fund its wider pipeline.

Moderna stock traded at 220.85 euros on Lang & Schwarz at 16:41 CET on Wednesday, November 4, 2026. The licensed quote was in euros; no Xetra comparison is included in this report.

Investors can follow the real-time quote of Moderna stock ahead of the earnings release.

Broader risk appetite and biotechnology sentiment will also shape the backdrop, alongside developments in the S&P 500.

More news and analyses on Moderna stock will follow as the earnings date approaches.